NCT/Study#

CDA5050/0006

Phase 1 open-label study with a novel triple mechanism of action IP in combination with Pembrolizumab for advanced malignancies.

Phase 1 open-label study with a novel triple mechanism of action IP in combination with Pembrolizumab for advanced malignancies.

DISEASE GROUP:
Phase 1
current phase:
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: